A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

Salehi, Sadaf; Sadeghi, Sara; Kalantari, Yasamin; Goodarzi, Azadeh

doi:10.1097/dad.0000000000002320

“…Most of these conditions are mild, so they will completely subside without any medication within a couple of days; therefore, obtaining a biopsy is rarely necessary. Our experience, in line with numerous studies, demonstrated that unusual and severe dermatological cases often require histopathological confirmation for accurate diagnosis; however, biopsies are infrequently performed, leading to speculative diagnoses and treatments [ 13 ].…”

Section: Discussionmentioning

confidence: 63%

“…Several studies have discussed various vaccine-induced mucocutaneous side effects. However, the administration of new booster doses, the emergence of new virus variants, and recurrent infections may result in a different pattern of symptoms [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Interesting Mucocutaneous Manifestations in COVID-19 Infection or Vaccination Confirmed by Histopathology: A Case Series

Pour Mohammad,

Noroozi,

Gholizadeh Mesgarha

et al. 2024

Case Rep Dermatol

0

View full text Add to dashboard Cite

Introduction: Mucocutaneous complications or adverse events due to SARS-CoV-2 infection or vaccination have been well delineated in the literature, respectively. Most eruptions are considered mild and self-limiting; however, for the atypical cases with a tentative clinical diagnosis, performing a biopsy and histopathological assessment is pivotal to confirm the diagnosis and subsequently prescribe a more tailored treatment. Despite the diverse reporting of such incidents globally, most studies restrict the rate of biopsied cases to less than 15%. Case Presentations: This case series elucidates 20 patients referred to the tertiary dermatology clinic, including 14 COVID-19 infection-related eruptions such as lichen planus (LP), cutaneous vasculitis, pityriasis rosea (PR), discoid lupus erythematosus, guttate psoriasis, sarcoidosis, Raynaud’s phenomenon, non-specific lesions resembling genital warts, Beau’s line, and one severe case of purpura fulminans with a promising outcome. Moreover, we presented six vaccine-induced cases comprising LP, urticarial vasculitis, PR, parapsoriasis, and localized morphea. The diagnosis of all challenging cases has been proven by histopathological evaluation. We included pertaining anamnesis details of each patient and vivid classifying images to pinpoint the morphologic features of each condition. Discussion: In line with our previous studies, the vaccine-induced eruptions were less severe compared to infection-related complications of COVID-19 and are mostly controllable by antihistamines and corticosteroid administration. Therefore, reporting such events should not impede COVID-19 vaccination in the general population.

show abstract

“…Notably, based on our experience and in line with multiple studies worldwide, the unusual, atypical and severe cases, which have been reported numerous times in literature, necessitate histopathological evaluation to verify their diagnosis. Despite their prevalence, biopsy is rarely performed in such circumstances which has led to speculative diagnosis and indefinite treatment (6). This case series embodies 20 patients who demonstrated 13 different patterns of mucocutaneous involvement following COVID-19 infection or vaccination, with proven diagnoses by histopathological assessment.…”

Section: Discussionmentioning

confidence: 99%

“…The development of COVID-19 vaccines considering the versatile manufacturing processes followed by their hurried approval and rapid distribution gave rise to a series of mucocutaneous incidents, which further escalated the COVID-19 dermatological concerns (5). The spectrum of vaccine-related mucocutaneous adverse events has been delineated by many studies, however, due to the administration of new booster doses, alterations in virus variants and recurrent infections, changes in pattern of symptoms are anticipated (6,7).…”

Section: Introductionmentioning

confidence: 99%

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

Mohammad

¹

,

Noroozi

²

,

Mesgarha

³

et al. 2023

Preprint

0

View full text Add to dashboard Cite

Mucocutaneous complications or adverse events due to SARS-CoV-2 infection or vaccination have been well-delineated in the literature, respectively. Most eruptions are considered to be mild and self-limiting; however, for the atypical cases which have a tentative clinical diagnosis, performing a biopsy and histopathological assessment is pivotal to confirm the diagnosis and subsequently prescribe a more tailored treatment. Despite the diverse reporting of such incidents globally, the rate of biopsied cases is restricted to less than 15% in most studies. This case series elucidates 20 patients referred to the tertiary dermatology clinic, including 14 COVID-19 infection-related eruptions such as Lichen Planus (LP), Cutaneous vasculitis, Pityriasis rosea (PR), Discoid lupus erythematosus, Guttate psoriasis, Sarcoidosis, Raynaud’s phenomenon, non-specific lesions resembling genital warts, Beau’s line and one severe case of purpura fulminans with a promising outcome. Moreover, we presented 6 vaccine-induced cases comprising LP, Urticarial vasculitis, PR, Parapsoriasis, and Localized Morphea. The diagnosis of all cases has been proven by histopathological evaluation. We included pertaining anamnesis details of each patient together with vivid classifying images to pinpoint the morphologic features of each condition. In line with our previous studies, the vaccine-induced eruptions were less severe compared to infection-related complications of COVID-19 and are mostly controllable by antihistamines and corticosteroids administration. Therefore, reporting such events should not hinder COVID-19 vaccination in the general population.

show abstract

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

Mesgarha

¹

,

Mohammad

²

,

Noroozi

³

et al. 2023

Preprint

0

View full text Add to dashboard Cite

Mucocutaneous complications or adverse events due to SARS-CoV-2 infection or vaccination have been well-delineated in the literature, respectively. Most eruptions are considered to be mild and self-limiting; however, for the atypical cases which have a tentative clinical diagnosis, performing a biopsy and histopathological assessment is pivotal to confirm the diagnosis and subsequently prescribe a more tailored treatment. Despite the diverse reporting of such incidents globally, the rate of biopsied cases is restricted to less than 15% in most studies. This case series elucidates 20 patients referred to the tertiary dermatology clinic, including 14 COVID-19 infection-related eruptions such as Lichen Planus (LP), Cutaneous vasculitis, Pityriasis rosea (PR), Discoid lupus erythematosus, Guttate psoriasis, Sarcoidosis, Raynaud’s phenomenon, non-specific lesions resembling genital warts, Beau’s line and one severe case of purpura fulminans with a promising outcome. Moreover, we presented 6 vaccine-induced cases comprising LP, Urticarial vasculitis, PR, Parapsoriasis, and Localized Morphea. The diagnosis of all cases has been proven by histopathological evaluation. We included pertaining anamnesis details of each patient together with vivid classifying images to pinpoint the morphologic features of each condition. In line with our previous studies, the vaccine-induced eruptions were less severe compared to infection-related complications of COVID-19 and are mostly controllable by antihistamines and corticosteroids administration. Therefore, reporting such events should not hinder COVID-19 vaccination in the general population.

show abstract

A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations

Abstract: Supplemental Digital Content is Available in the Text.

Cited by 3 publications

References 148 publications

Interesting Mucocutaneous Manifestations in COVID-19 Infection or Vaccination Confirmed by Histopathology: A Case Series

Interesting Mucocutaneous Manifestations in COVID-19 Infection or Vaccination Confirmed by Histopathology: A Case Series

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

A case series of interesting mucocutaneous presentations in COVID-19 infection or post COVID-19 vaccination confirmed by biopsy and histopathologic assessment

Contact Info

Product

Resources

About